Showing posts with label NIH. Show all posts
Showing posts with label NIH. Show all posts

Thursday, 26 May 2016

Princess Health and Are You Ready for Some (Political) Football? - the NFL, Concussion Research, the NIH, and the Revolving Door. Princessiccia

Probably because it involved the favorite American sport, the controversy about the risk of concussions to professional National Football League (NFL) players, and how the NFL has handled the issue is very well known.  A recent article in Stat, however, suggested that one less well known aspect of the story overlaps some issues to concern to Health Care Renewal.

Allegations that a Prominent Physician and NFL Official Tried to Influence the NIH Grant Review Process

The article began,

Dr. Elizabeth Nabel, president of Boston�s Brigham and Women�s Hospital [BWH] and one of the nation�s most prominent medical executives, was part of a National Football League effort to 'steer funding' for a landmark concussion study away from a group of respected brain researchers, according to a congressional committee report that was sharply critical of the league.

The report found that the NFL 'inappropriately attempted to influence' the National Institutes of Health�s [NIH] grant selection process.

Dr Nabel, in fact, not only runs the BWH, a renowned teaching hospital and major component of Partners Healthcare, but also serves as the "chief health and medical advisor" to the NFL. Anyone who has followed even a bit of the media coverage about the NFL and concussions affecting football players knows that the NFL could be negatively affected by any more research that associates playing professional football, concussions, and the adverse effects of concussions. 

The Stat article chronicled the intricate communications between Dr Nabel and the NIH as documented by a report from the Democratic staff of the House Committee on Energy and Commerce.

 It cited a series of communications between NFL representatives, including Nabel, and officials of the NIH, and a foundation that accepts gifts from private donors to support NIH research. The discussions began after the NIH decided last year to award a $16 million grant to a research team led by Dr. Robert Stern of Boston University � but before the award was publicly announced.

The money for the grant was to come from a donation pledged by the NFL to the Foundation for the National Institutes of Health, and league officials say they were concerned about aspects of Stern�s group and the proposed study.

Research by Stern�s team and BU colleagues has helped establish a link between football and chronic traumatic encephalopathy, long-term brain damage that�s been observed in a growing number of athletes, including former NFL players, who suffered repeated head injuries.

The implication seems to be that this research group might be counted on to fearlessly pursue research even if the outcomes suggested that playing football might lead to adverse medical effects, which might not be so good for the NFL's interests.  So,

Nabel, who knows the NIH well from her 10 years working as a high-level manager in the agency, sent two emails to Dr. Walter Koroshetz, director of the National Institute of Neurological Disorders and Stroke [NINDS], according to the report. That�s the NIH branch that was awarding the grant.

In one email on June 23, 2015, she wrote, 'I am taking a neutral stance here,' while noting a concern about a potential conflict of interest: members of the NIH grant review panel had coauthored papers with two researchers that she had heard might be receiving the grant � Dr. Ann McKee and Dr. Robert Cantu of BU.

Later that day, she wrote Koroshetz that 'a Dr. Stern, who may also be with this group, has filed independent testimony in the NFL/Players Association settlement.'

Indeed, Stern was critical of how the settlement would be administered, pointing out flaws with the neuropsychological tests that the league proposed using to determine how to compensate injured players.


 Notwithstanding that Dr Nabel had an obvious conflict of interest herself: she worked for the NFL.  In any case,  

'I hope this group is able to approach their research in an unbiased manner,' Nabel�s email continued, the report says.

Nabel sent Stern�s testimony to Koroshetz, according to the report.

'My sole objective,' Nabel said in her statement, was to ask her former NIH colleagues to 'ensure there were no conflicts of interest among grant applicants.'

The NIH found no conflicts involving the grant review panel and stuck with its decision to award the grant to the Stern group. It ended up using internal funds, not the NFL money, to pay for the grant.

The NIH told STAT it agrees with the 'characterization of events in the report.'
An Affront to the Sanctity of the Grant Review Process?

Although Dr Nabel and the NFL asserted that they acted appropriately at all times, neither the committee staff nor one very prominent ethicist agreed,

The committee report said that Koroshetz disagreed ..., and said he was aware of no other instance where a donor raised objections to a grantee prior to the issuance of a notice of grant award.'

'The NFL�s characterization of the appropriateness of its actions suggests a lack of understanding of the importance of the NIH�s independent peer review process,' the committee report states.

Nabel�s spokeswoman said Koroshetz never told Nabel her actions were inappropriate. 'In fact, all of their interactions were very collegial and cordial,' she said.

I will interject that the question was not whether Dr Nabel was hostile or bullying, but was whether she tried to inappropriately influence the grant review process.  So also,

Arthur Caplan, a professor of bioethics at New York University, said Nabel�s actions, as described in the report, risk harming Nabel�s reputation and that of the Brigham. 'When she did anything to try to shape the selection of investigators or challenge the objectivity' of the grant selection process, he said, 'she had to know that that was 100 percent inappropriate, 100 percent unacceptable.'

Having served on numerous NIH and Agency for Healthcare Research and Quality (AHRQ) review committees (known as "study sections"),  let me add some context at this point.  Study section members must meet rigorous standards for freedom from conflicts of interest.  They also fiercely guard their independence.  The grant reviews they construct are supposed to be entirely about the scientific, clinical and public health merit of the proposals, and the scores they give proposals are the most important determinants of whether it gets funding.  Funding decisions are actually made by agency staff and advisory boards, but are supposed to depend only on the reviews and the general priority of the proposals' topics.  Nobody - I repeat, nobody - outside of this process is supposed to influence the funding decisions.

So the notion that big wigs from big outside organizations with vested interests in how a particular research project might turn out were communicating with top NIH officials about grant proposals, and that the officials allowed them to continue to communicate, and allowed even the chance they would be influenced by their communication strikes this old reviewer, to quote Dr Caplan, as "100 inappropriate, 100 percent unacceptable."

Did the Revolving Door Enable the Attempt to Influence NIH Grant Review?

Not directly discussed in the Stat article, however, was why Dr Koroshetz, director of NINDS, was willing to accept, if not agree with Dr Nabel's communications.  The article did note that Dr Nabel was a former "high-level manager" at the NIH.  In fact, according to her official Brigham and Womens' Hospital biography, Dr Nabel was director of the US National Heart, Lung and Blood Institute from 2005-2009.  She became CEO of the BWH in 2010.  Thus, she was a former top NIH leader who once held a rank commensurate with that held by Dr Koroshetz.

But wait, there is more.  Also according to her official BWH biography, Dr Nabel's husband is one  Gary Nabel, now the chief scientific officer at Sanofi.  Dr Gary Nabel, in turn, was Director of the Vaccine Research Center at the National Institute for Allergy and Infectious Diseases (NIAID), another NIH institute, through 2012, but then according to Science, became chief scientific officer at Sanofi. So Dr Nabel's husband was also a high-ranking NIH leader, although apparently not as high-ranking as his spouse and the NINDS director with whom she communicated. 

Thus it appears that maybe Dr Nabel had outsized influence at the NIH and on the NINDS director because she was a former NHLBI director, and the spouse of a former high-ranking NIAID leader.  Her attempts to influence the NIH grant application process therefore appear to be a possible manifestation, albeit delayed, and partially at one spousal remove, of the revolving door pheonomenon.

We have noted that the revolving door is a species of conflict of interest. Worse, some experts have suggested that the revolving door is in fact corruption.  As we noted here, the experts from the distinguished European anti-corruption group U4 wrote,

The literature makes clear that the revolving door process is a source of valuable political connections for private firms. But it generates corruption risks and has strong distortionary effects on the economy, especially when this power is concentrated within a few firms.
  This case suggests how the revolving door may enable certain of those with private vested interests to have excess influence, way beyond that of ordinary citizens, on how the government works.

Worse, this case also suggests how it seems that the country is increasingly run by a cozy group of insiders with ties to both government and industry.  In fact, just a little more digging reveals that a key player in this case has even more ties to big private health care organizations.  According to ProPublica, in the last three months of 2014, Dr Elizabeth Nabel received $26,070 from Medtronic, mainly for food, travel and lodging, but which included $8572 for "promotional speaking/ other."  In 2015, she was appointed to the board of directors of Medtronic, despite not having previously owned any Medtronic stock, according to the company's 2015 proxy statement.  Also in 2015, she was appointed to the board of directors of Moderna Therapeutics.    Her husband, as noted above, now works as chief scientific officer for Sanofi.

So, as we have said before.... The continuing egregiousness of the revolving door in health care shows how health care leadership can play mutually beneficial games, regardless of the their effects on patients' and the public's health.  Once again, true health care reform would cut the ties between government and corporate leaders and their cronies that have lead to government of, for and by corporate executives rather than the people at large.

Video addendum: the beginning of "League of Denial" from PBS Frontline



ADDENDUM (29 May, 2016) - This post was republished on the Naked Capitalism blog.

Friday, 18 September 2015

Princess Health and A Quiet Turn of the Revolving Door - Director of NIMH to Go Directly to Google Life Sciences. Princessiccia

Princess Health and A Quiet Turn of the Revolving Door - Director of NIMH to Go Directly to Google Life Sciences. Princessiccia

Amidst a lot of health care news, the job plans of Dr Thomas Insel, currently the director of the National Institute of Mental Health (part of the US National Institute of Health) made a very small splash.  The most comprehensive account was in the New York Times.

Dr. Thomas R. Insel, the director of the National Institute of Mental Health, announced on Tuesday that he planned to step down in November, ending his 13-year tenure at the helm of the world�s leading funder of behavioral-health research to join Google Life Sciences, which seeks to develop technologies for early detection and treatment of health problems.

As noted in the NYT article, Dr Insel had great influence over the direction of mental health research and policy,

Dr. Insel took over the N.I.M.H. in 2002 and steered funding toward the most severe mental disorders, like schizophrenia, and into basic biological studies, at the expense of psychosocial research, like new talk therapies. His critics � and there were plenty � often noted that biological psychiatry had contributed nothing useful yet to diagnosis or treatment, and that Dr. Insel�s commitment to basic science was a costly bet, with uncertain payoffs.

A Modern Healthcare article documented Dr Insel's specific organizational roles beyond his directorship that could have influenced research and policy,

Insel chaired the Interagency Autism Coordinating Committee, which is a federal advisory committee that coordinates autism research and services and was established by Congress.

Insel also co-chaired the Blueprint for Neuroscience Research, which supported the pioneering Human Connectome Project, a project to map the human brain, and the NIH Brain Research through Advancing Innovative Neurotechnologies program, which aims to accelerate the development and application of innovative technologies to map brain circuits.

Insel also headed up the Common Fund efforts in Molecular Libraries, Single Cell Biology, and Genotype-Tissue Expression.

Comment

So Dr Insel clearly helped steer current US government mental health care research and policy towards its current course.  Now he is going directly, not with any sort of delay or waiting period, to a commercial firm poised to take advantage of the current direction of US mental health care research and policy.

Although more subtle than, say, a leader of a government regulatory agency departing for a position at a company regulated by that agency, this, in my humble opinion, appears to be an example of the revolving door.  Certainly it fits the broad 2011 Transparency International definition,

The term �revolving door� refers to the movement of individuals between positions of public office and jobs in the private sector, in either direction.

Despite this, as far as I can tell, no one else so far has referred to this job transfer as an example of the revolving door.

Furthermore, as we noted here, the revolving door can be veiwed as a species of conflict of interest.  Government officials who can look forward to extremely lucrative employment in health care industry may be much more inclined to seem friendly to the industry while in office.  Government officials who just came from industry are likely to maintain their industry mindset and be mindful of their industry friends.

Worse, some experts have suggested that the revolving door is in fact corruption.  As we noted here, the experts from the distinguished European anti-corruption group U4 wrote,


The literature makes clear that the revolving door process is a source of valuable political connections for private firms. But it generates corruption risks and has strong distortionary effects on the economy, especially when this power is concentrated within a few firms.

We have discussed Dr Insel's approach to conflicts of interest before.  Note that Dr Bernard Carroll, posting on this blog, has written extensively about Dr Insel's apparently rather lax approach to conflict of interest issues while he was at NIH raised by the case of Dr Charles Nemeroff.  Look herehere, here, and here.  Recapping these, I noted that Dr Insel later confessed that his statements about these issues "may be viewed as misleading."

Nonetheless, as far as I can tell, no one else so far has used the term conflict of interest in discussing Dr Insel's new job.  The anechoic effect continues.

As we have said endlessly, most recently here, the ongoing and increasing revolving door phenomenon clearly suggests excess coziness between industry and government, now to the extent that industry and government leaders of health care are becoming interchangeable.  This suggests that health care is increasingly run by this cozy ingroup, who very likely put their own interests ahead of those of patients and the public.

The continuing egregiousness of the revolving door in health care shows how health care leadership can play mutually beneficial games, regardless of the their effects on patients' and the public's health.  Once again, true health care reform would cut the ties between government and corporate leaders that have lead to government of, for and by corporate executives rather than the people at large

ADDENDUM (24 October, 2015) - This post was republished in OpEdNews.

Tuesday, 31 May 2005

Princess Health and Editorial Argues Against Softening NIH Conflict of Interest Rules. Princessiccia

Princess Health and Editorial Argues Against Softening NIH Conflict of Interest Rules. Princessiccia

The question of whether the NIH should soften its now stringent conflict of interest rules re-surfaced in an editorial in the Hartford Courant. Some choice quotes:

  • "Prodded by newspaper exposes and congressional inquiries, the NIH instituted a series of reforms. Scientists were barred from accepting compensation from the biomedical industry. Also, the NIH's top 7,000 staffers were prohibited from owning stock in individual medical companies, while all other employees were directed to limit their holdings to $15,000."



  • "The stock restrictions have raised the ire of a group calling itself the Assembly of Scientists, whose members have threatened to leave the NIH if the reforms aren't scaled back. Health and Human Services Secretary Mike Leavitt, who oversees the NIH, said he's considering their request, calling it a would-be 'softening of the conflict-of-interest policy.'



  • "In truth, it's more like selling out. Fortunes can be made or lost in biomedical stocks, based on the development or demise of breakthrough drugs and treatments. If researchers were allowed to replenish their portfolios with drug industry stocks, the temptations and biases of recent years would return in force. Mr. Leavitt should stand pat. The NIH's conflict-of-interest policy doesn't need any loopholes blown through it. "


    • Princess Health and  Editorial Argues Against Softening NIH Conflict of Interest Rules.Princessiccia

      Princess Health and Editorial Argues Against Softening NIH Conflict of Interest Rules.Princessiccia

      The question of whether the NIH should soften its now stringent conflict of interest rules re-surfaced in an editorial in the Hartford Courant. Some choice quotes:

    • "Prodded by newspaper exposes and congressional inquiries, the NIH instituted a series of reforms. Scientists were barred from accepting compensation from the biomedical industry. Also, the NIH's top 7,000 staffers were prohibited from owning stock in individual medical companies, while all other employees were directed to limit their holdings to $15,000."



    • "The stock restrictions have raised the ire of a group calling itself the Assembly of Scientists, whose members have threatened to leave the NIH if the reforms aren't scaled back. Health and Human Services Secretary Mike Leavitt, who oversees the NIH, said he's considering their request, calling it a would-be 'softening of the conflict-of-interest policy.'



    • "In truth, it's more like selling out. Fortunes can be made or lost in biomedical stocks, based on the development or demise of breakthrough drugs and treatments. If researchers were allowed to replenish their portfolios with drug industry stocks, the temptations and biases of recent years would return in force. Mr. Leavitt should stand pat. The NIH's conflict-of-interest policy doesn't need any loopholes blown through it. "


      • Sunday, 24 April 2005

        Princess Health and NIH Dissidents Keep Fighting Conflict of Interest Rules. Princessiccia

        Princess Health and NIH Dissidents Keep Fighting Conflict of Interest Rules. Princessiccia

        The LA Times reported that over at the National Institutes of Health (NIH), the dissident Assembly of Scientists is ramping up its fight to preserve the ability of NIH physicians, scientists, and leaders to personally hold pharmaceutical and biotechnology stocks, and to take fees in addition to their salaries to consult for pharmaceutical and biotechnology companies.
        The Assembly has hired the firm of Arent Fox PLLC as its representative. The LA Times article alleged that Arent Fox also has represented makers of pharmaceuticals, medical devices, and dietary supplements, and one of its clients is the Biotechnology Industry Organization. Apparently, the Assembly of Scientists is getting these services at a discount, for reasons that are unclear. Furthermore, it turns out that Rep. Chris Van Hollen (D-MD), who asked NIH Director Zerhouni to delay implementation of more stringent conflict of interest rules, is a former partner in Arent Fox.
        My comment is that the more that top NIH scientists and leaders seem focused on keeping their lucrative outside consulting work for biotechnology and pharmaceutical corporations, the more doubts will be raised about where their true loyalties lie. Are they first loyal public servants, or industry consultants? If the latter, are their writings and actions primarily meant to advance science, or advance the commercial interests of their consulting clients?
        Princess Health and  NIH Dissidents Keep Fighting Conflict of Interest Rules.Princessiccia

        Princess Health and NIH Dissidents Keep Fighting Conflict of Interest Rules.Princessiccia

        The LA Times reported that over at the National Institutes of Health (NIH), the dissident Assembly of Scientists is ramping up its fight to preserve the ability of NIH physicians, scientists, and leaders to personally hold pharmaceutical and biotechnology stocks, and to take fees in addition to their salaries to consult for pharmaceutical and biotechnology companies.
        The Assembly has hired the firm of Arent Fox PLLC as its representative. The LA Times article alleged that Arent Fox also has represented makers of pharmaceuticals, medical devices, and dietary supplements, and one of its clients is the Biotechnology Industry Organization. Apparently, the Assembly of Scientists is getting these services at a discount, for reasons that are unclear. Furthermore, it turns out that Rep. Chris Van Hollen (D-MD), who asked NIH Director Zerhouni to delay implementation of more stringent conflict of interest rules, is a former partner in Arent Fox.
        My comment is that the more that top NIH scientists and leaders seem focused on keeping their lucrative outside consulting work for biotechnology and pharmaceutical corporations, the more doubts will be raised about where their true loyalties lie. Are they first loyal public servants, or industry consultants? If the latter, are their writings and actions primarily meant to advance science, or advance the commercial interests of their consulting clients?

        Monday, 11 April 2005

        Princess Health and "Climate of Alarm Described at NIH". Princessiccia

        Princess Health and "Climate of Alarm Described at NIH". Princessiccia

        And here is yet another story about problems at the NIH, this time allegations about intimidation of whistle-blowers. The Associated Press obtained testimony charging that NIH officials squelched safety concerns tin the rush to try "to cure AIDS." For example,
        • "It can be fairly uncomfortable. There are a number of things that you just don't talk about. You don't hold up any projects even if you feel there are safety issues for certain projects." (Testimony by Betsy Smith, NIAID)
        • "I think we [safety officials] got in the way and that we were an impediment to the science." Division managers were "totally unsupportive" of safety and were responding to "tremendous pressure" from drug companies. "I think the culture was certainly strong for a period of time that the ends could justify the means." (Testimony by Mary Anne Luzar, Ph.D., Chief Regulatory Affairs Section, Pharmaceutical and Regulatory Affairs Branch, DAIDS)
        Yet more clean up work is ahead for Director Zernouni. But this provides yet more justification for his argument that widespread changes are needed.
        Princess Health and  "Climate of Alarm Described at NIH".Princessiccia

        Princess Health and "Climate of Alarm Described at NIH".Princessiccia

        And here is yet another story about problems at the NIH, this time allegations about intimidation of whistle-blowers. The Associated Press obtained testimony charging that NIH officials squelched safety concerns tin the rush to try "to cure AIDS." For example,
        • "It can be fairly uncomfortable. There are a number of things that you just don't talk about. You don't hold up any projects even if you feel there are safety issues for certain projects." (Testimony by Betsy Smith, NIAID)
        • "I think we [safety officials] got in the way and that we were an impediment to the science." Division managers were "totally unsupportive" of safety and were responding to "tremendous pressure" from drug companies. "I think the culture was certainly strong for a period of time that the ends could justify the means." (Testimony by Mary Anne Luzar, Ph.D., Chief Regulatory Affairs Section, Pharmaceutical and Regulatory Affairs Branch, DAIDS)
        Yet more clean up work is ahead for Director Zernouni. But this provides yet more justification for his argument that widespread changes are needed.
        Princess Health and "The Price of NIH Credibility". Princessiccia

        Princess Health and "The Price of NIH Credibility". Princessiccia

        An excellent editorial in the Los Angeles Times. Let me just provide some quotes.
        • "Protesting NIH staff scientists and members of Congress opposing the new regulations would have us think [NIH Director] Zerhouni intends to bulldoze the agency's 300-acre campus in Bethesda, MD, and turn it into a garment district sweatshop."
        • "Zerhouni's critics claim that the new rules will lead to a cataclysmic brain drain. Yes, a few people might leave. But the rules also should bolster the agency's status as one of the few places where scientists can work with true autonomy, free from the increasingly brazen control that biomedical industries are exerting over research."
        • "A Government Accountability [sic] Office study released two months ago found that the previous NIH policies 'could call into question the quality and independence of federally funded research.' There could hardly be a better reason for change."
        • "At Senate hearings last week, Sen. Tom Harking (D-Iowa) sided with the complaining scientists and dangled a possible NIH budget increase in an implicit tit-for-tat for softer rules. That's just strong-arming."
        • "Zerhouni is trying to restore scientific credibility to an agency that had allowed one of its top scientists, P. Trey Sutherland III, to pocket half a million dollars from Pfizer Inc. even as he was evaluating Pfizer drugs for NIH. Would [Senator] Harkin want to buy a drug for his family that was developed in this manner?"
        Couldn't say it better myself.
        Princess Health and  "The Price of NIH Credibility".Princessiccia

        Princess Health and "The Price of NIH Credibility".Princessiccia

        An excellent editorial in the Los Angeles Times. Let me just provide some quotes.
        • "Protesting NIH staff scientists and members of Congress opposing the new regulations would have us think [NIH Director] Zerhouni intends to bulldoze the agency's 300-acre campus in Bethesda, MD, and turn it into a garment district sweatshop."
        • "Zerhouni's critics claim that the new rules will lead to a cataclysmic brain drain. Yes, a few people might leave. But the rules also should bolster the agency's status as one of the few places where scientists can work with true autonomy, free from the increasingly brazen control that biomedical industries are exerting over research."
        • "A Government Accountability [sic] Office study released two months ago found that the previous NIH policies 'could call into question the quality and independence of federally funded research.' There could hardly be a better reason for change."
        • "At Senate hearings last week, Sen. Tom Harking (D-Iowa) sided with the complaining scientists and dangled a possible NIH budget increase in an implicit tit-for-tat for softer rules. That's just strong-arming."
        • "Zerhouni is trying to restore scientific credibility to an agency that had allowed one of its top scientists, P. Trey Sutherland III, to pocket half a million dollars from Pfizer Inc. even as he was evaluating Pfizer drugs for NIH. Would [Senator] Harkin want to buy a drug for his family that was developed in this manner?"
        Couldn't say it better myself.

        Saturday, 2 April 2005

        Princess Health and More Unrest Over the New NIH Ethics Rules. Princessiccia

        Princess Health and More Unrest Over the New NIH Ethics Rules. Princessiccia

        The Washington Post reports yet more unrest among top NIH employees about the new ethics rules.
        • Another prominenet leader is stepping down because he can't comply with the new rules. James F. Battey, the Director of the National Institute on Deafness and Other Communicative Disorders, said "I manage a family trust ... which supports the education of my father's seven grandchildren, and it contains assets I'm told I'd have to divest. This would cost a lot of money, and I can't do that to my family."
        • A dissenting group of "senior agency scientists," complained that they would have to get permission for practically any outside activity, "whether paid or not, from singing in a jazz group to selling art or jewelry, from volunteering at charity organizations to membership in a school or community organization...." from the NIH. "It is intrusive and scary. It suggests the NIH owns our lives away from work."
        • Ashani Weerarartna of the National Institute on Aging was told she could not accept a $200 train ticket from a "physicians' education group" to present a paper. "I felt awful. I had to call and tell them to find someone else."
        • Furthermore, NIH workers complained that they "cannot hold executive postions - even on a volunteer basis - with trade or professional organizations..." Regarding this, Robert L. Nussbaum, Chief, Genetic Disease Research Branch,National Human Genome Research Institute, said "But what I'm really worried about is backlash from the organizations.""We will be cut off, disenfranchised from our academic colleagues."
        An interesting theme here, in my humble opinion, is how those who complain about the new regulations seem to exaggerate their impact.
        • Let's start with Dr. Battey, who also does seem to represent a very special case. I would imagine he could continue to manage his family trust himself if he were willing to sell individual stocks of pharmaceutical and biotechnology companies. Why that would be so expensive is unclear, unless he chose some very bad investments. Furthermore, he could re-invest the money in say, mutual funds that specialize in pharma or biotech. On the other hand, he could simply hire a professional money manager.
        • The dissenting NIH employees seem to have exaggerated the effect of the regulations, as summarized here, on outside activities unrelated to their work at the agency.
        • If the meeting were so important, why couldn't Weerarartna ask the NIH to pay her way, or pay her own way? On the other hand, was the "physicians' education group" actually a commercial CME source, or was it funded by pharma or biotech money?
        • Why couldn't Dr Nussbaum participate in some way other than an "executive" role in the organization? If those "executive positions" were the only members not to feel "cut off, disenfranchised" from this organization, why would anyone want to be a member of it?
        Again, let me reiterate, NIH leaders have the privilege of working for what many consider to be the world's premier biomedical research institution. In holding such positions, their speech and actions ought to reflect their scientific knowledge and their commitment to the public good. Major personal financial involvements with outside entities, especially for-profit manufacturers of pharmaceuticals and devices, raise questions about whose interests they are really serving. As Director Zerhouni has said, "It is undermining in a profound way � more profound than I personally realized at the beginning of the process � the integrity of our research and our ability to maintain public trust in our research.�
        If NIH salaries are too low to attract competent scientists and physicians, they should be raised. But an NIH position should not be license to seek lucrative after-hours employment for industry.
        Princess Health and  More Unrest Over the New NIH Ethics Rules.Princessiccia

        Princess Health and More Unrest Over the New NIH Ethics Rules.Princessiccia

        The Washington Post reports yet more unrest among top NIH employees about the new ethics rules.
        • Another prominenet leader is stepping down because he can't comply with the new rules. James F. Battey, the Director of the National Institute on Deafness and Other Communicative Disorders, said "I manage a family trust ... which supports the education of my father's seven grandchildren, and it contains assets I'm told I'd have to divest. This would cost a lot of money, and I can't do that to my family."
        • A dissenting group of "senior agency scientists," complained that they would have to get permission for practically any outside activity, "whether paid or not, from singing in a jazz group to selling art or jewelry, from volunteering at charity organizations to membership in a school or community organization...." from the NIH. "It is intrusive and scary. It suggests the NIH owns our lives away from work."
        • Ashani Weerarartna of the National Institute on Aging was told she could not accept a $200 train ticket from a "physicians' education group" to present a paper. "I felt awful. I had to call and tell them to find someone else."
        • Furthermore, NIH workers complained that they "cannot hold executive postions - even on a volunteer basis - with trade or professional organizations..." Regarding this, Robert L. Nussbaum, Chief, Genetic Disease Research Branch,National Human Genome Research Institute, said "But what I'm really worried about is backlash from the organizations.""We will be cut off, disenfranchised from our academic colleagues."
        An interesting theme here, in my humble opinion, is how those who complain about the new regulations seem to exaggerate their impact.
        • Let's start with Dr. Battey, who also does seem to represent a very special case. I would imagine he could continue to manage his family trust himself if he were willing to sell individual stocks of pharmaceutical and biotechnology companies. Why that would be so expensive is unclear, unless he chose some very bad investments. Furthermore, he could re-invest the money in say, mutual funds that specialize in pharma or biotech. On the other hand, he could simply hire a professional money manager.
        • The dissenting NIH employees seem to have exaggerated the effect of the regulations, as summarized here, on outside activities unrelated to their work at the agency.
        • If the meeting were so important, why couldn't Weerarartna ask the NIH to pay her way, or pay her own way? On the other hand, was the "physicians' education group" actually a commercial CME source, or was it funded by pharma or biotech money?
        • Why couldn't Dr Nussbaum participate in some way other than an "executive" role in the organization? If those "executive positions" were the only members not to feel "cut off, disenfranchised" from this organization, why would anyone want to be a member of it?
        Again, let me reiterate, NIH leaders have the privilege of working for what many consider to be the world's premier biomedical research institution. In holding such positions, their speech and actions ought to reflect their scientific knowledge and their commitment to the public good. Major personal financial involvements with outside entities, especially for-profit manufacturers of pharmaceuticals and devices, raise questions about whose interests they are really serving. As Director Zerhouni has said, "It is undermining in a profound way � more profound than I personally realized at the beginning of the process � the integrity of our research and our ability to maintain public trust in our research.�
        If NIH salaries are too low to attract competent scientists and physicians, they should be raised. But an NIH position should not be license to seek lucrative after-hours employment for industry.

        Thursday, 31 March 2005

        Princess Health and NIH Update: Resistance Against New Conflict of Interest Rules Continues. Princessiccia

        Princess Health and NIH Update: Resistance Against New Conflict of Interest Rules Continues. Princessiccia

        The New England Journal of Medicine this week has a good summary by Robert Steinbrook of the latest developments at the NIH. In particular, it has a clear table of the new, more stringent regulations temporarily put in place by Director Zerhouni.
        These included:
        • Prohibition of employment with pharmaceutical and biotechnology companies, research institutions that receive NIH grants and contracts, health care providers and insurers, and related trade, professional, or similar associations
        • Prohibition of compensated teaching or writing for these organizations
        • Prohibition of self-employed business activity involving sale or promotion of products or services of a pharmaceutical or biotechnology company or a health care provider or insurer
        • Prohibition of holding stock in biotechnology or pharmaceutical companies for employees who must file financial disclosure reports, a $15,000 limit in holdings in any one company for other employees
        • Prohibition for senior employees only of the receipt of most awards worth more than $200, and a similar prohibition for all employees of such awards from an organization which is involved with the employees work
        • In general, outside teaching, clinical, scientific writing, and scientific editing activities are permitted as long as they comply with other standards.
        It also includes a narrative of how Zerhouni changed his mind about the need for such regulations. Much of its contents has already appeared on Health Care Renewal, but it does have some important new items.
        One is that the new regulations at the NIH parallel those already in place at regulatory agencies, such as the Food and Drug Administration and the Securities and Exchange Commission. This was in part driven by the realization that NIH decisions can have "increasingly powerful influence ... on financial markets." Moreover, Zerhouni felt the regulations were in response to activities by high NIH officials that "really were purely and imply what you would call product-endorsement activities, speaking for a company on behalf of a product to entice physicians to prescribe that product at greater levels."

        The article also mentions the opposition to these new regulations that Zerhouni has encountered. Furthermore, yesterday, the Washington Post reported that apparently a physician recently nominated to head the National Institute of Environmental Health Sciences now has "serious concerns about taking the job under the new rules." "His primary concenr is that he would be unable to recruit or retain top talent."

        The NIH is, as Steinbrook stated, is "regarded as the world's premier biomedical research institution." So, it amazes me that some people don't think the could manage to work in full-time leadership positions at the NIH because they no longer could also work for certain outside organizations, or simultaneously pursue self-employed business activity involving the products of such organization. Are NIH salaries really so low that its high level employees need second jobs to get along economically? Or do people now feel so entitled to lucrative side-employment with industry that the notion of loyal service to the public means nothing? But maybe such people are not those who should be working at "the world's premier biomedical research institution."
        Princess Health and  NIH Update: Resistance Against New Conflict of Interest Rules Continues.Princessiccia

        Princess Health and NIH Update: Resistance Against New Conflict of Interest Rules Continues.Princessiccia

        The New England Journal of Medicine this week has a good summary by Robert Steinbrook of the latest developments at the NIH. In particular, it has a clear table of the new, more stringent regulations temporarily put in place by Director Zerhouni.
        These included:
        • Prohibition of employment with pharmaceutical and biotechnology companies, research institutions that receive NIH grants and contracts, health care providers and insurers, and related trade, professional, or similar associations
        • Prohibition of compensated teaching or writing for these organizations
        • Prohibition of self-employed business activity involving sale or promotion of products or services of a pharmaceutical or biotechnology company or a health care provider or insurer
        • Prohibition of holding stock in biotechnology or pharmaceutical companies for employees who must file financial disclosure reports, a $15,000 limit in holdings in any one company for other employees
        • Prohibition for senior employees only of the receipt of most awards worth more than $200, and a similar prohibition for all employees of such awards from an organization which is involved with the employees work
        • In general, outside teaching, clinical, scientific writing, and scientific editing activities are permitted as long as they comply with other standards.
        It also includes a narrative of how Zerhouni changed his mind about the need for such regulations. Much of its contents has already appeared on Health Care Renewal, but it does have some important new items.
        One is that the new regulations at the NIH parallel those already in place at regulatory agencies, such as the Food and Drug Administration and the Securities and Exchange Commission. This was in part driven by the realization that NIH decisions can have "increasingly powerful influence ... on financial markets." Moreover, Zerhouni felt the regulations were in response to activities by high NIH officials that "really were purely and imply what you would call product-endorsement activities, speaking for a company on behalf of a product to entice physicians to prescribe that product at greater levels."

        The article also mentions the opposition to these new regulations that Zerhouni has encountered. Furthermore, yesterday, the Washington Post reported that apparently a physician recently nominated to head the National Institute of Environmental Health Sciences now has "serious concerns about taking the job under the new rules." "His primary concenr is that he would be unable to recruit or retain top talent."

        The NIH is, as Steinbrook stated, is "regarded as the world's premier biomedical research institution." So, it amazes me that some people don't think the could manage to work in full-time leadership positions at the NIH because they no longer could also work for certain outside organizations, or simultaneously pursue self-employed business activity involving the products of such organization. Are NIH salaries really so low that its high level employees need second jobs to get along economically? Or do people now feel so entitled to lucrative side-employment with industry that the notion of loyal service to the public means nothing? But maybe such people are not those who should be working at "the world's premier biomedical research institution."